Which of the following antifungal drug is developing drug resistance and has not been prescribed for tinea cruris and tinea corporis for the last 2 years?
**Core Concept**
The development of antifungal drug resistance is a significant concern in the treatment of fungal infections. This phenomenon is often associated with the overuse or misuse of antifungal agents, leading to the selection of resistant fungal strains.
**Why the Correct Answer is Right**
The correct answer is **C. Terbinafine**. Terbinafine is an allylamine antifungal agent that exerts its effects by inhibiting squalene epoxidase, an enzyme crucial for the fungal cell membrane synthesis. However, the widespread use of terbinafine for treating dermatophytic infections, such as tinea cruris and tinea corporis, has led to the development of resistance. As a result, terbinafine is no longer the preferred treatment option for these conditions.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because griseofulvin is an antifungal agent that is still used to treat tinea cruris and tinea corporis, particularly in patients with onychomycosis.
* **Option B:** This option is incorrect because fluconazole is an azole antifungal agent that is commonly used to treat a variety of fungal infections, including tinea cruris and tinea corporis.
* **Option D:** This option is incorrect because itraconazole is another azole antifungal agent that is often used to treat fungal infections, including tinea cruris and tinea corporis.
**Clinical Pearl / High-Yield Fact**
It is essential to note that the development of antifungal drug resistance is a growing concern, and the overuse or misuse of antifungal agents can exacerbate this issue. As a result, it is crucial to use antifungal agents judiciously and to consider alternative treatment options when possible.
**Correct Answer:** C. Terbinafine